Table 1 Characteristics of RA patients including demographics, disease activity scores, and DMARD use.
From: Molecular Profile of Peripheral Blood Mononuclear Cells from Patients with Rheumatoid Arthritis
ID | Age, years | Sex | RF titer | Erosions | DMARD use | DAS |
|---|---|---|---|---|---|---|
RA1 | 61 | F | — | + | Prednisolone 5 mg/d, methotrexate 15 mg/wk | 3.9 |
RA2 | 66 | F | 1/5120 | + | Prednisolone 7.5 mg/d, methotrexate 20 mg/wk, sulfasalazine 500 mg BD | 4.5 |
RA3 | 46 | F | 1/640 | + | Methotrexate 15 mg/wk, hydroxychloroquine 200 mg BD | 3.5 |
RA4 | 52 | F | 1/640 | − | Methotrexate 12.5 mg/wk | 3.6 |
RA5 | 55 | F | 1/320 | + | Methotrexate 12.5 mg/wk, hydroxychloroquine 200 mg BD | 3.3 |
RA6 | 35 | F | 1/2560 | + | — | 3.0 |
RA7 | 74 | M | 1/320 | + | Methotrexate 7.5 mg/wk | 3.5 |
RA8 | 77 | M | 1/20400 | + | Prednisolone 7.5 mg/d, methotrexate 17.5 mg/wk | 3.2 |
RA 9 | 49 | F | 1/1250 | + | Methotrexate 10 mg/wk | 2.9 |